KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Tax Assets: 2009-2010

  • Alnylam Pharmaceuticals' Current Deferred Tax Assets was N/A to $1.9 million in Q3 2010 from the same period last year, while for Sep 2010 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2009, which is N/A change from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Current Deferred Tax Assets stood at $1.9 million for Q3 2010, which was up 0.31% from $1.9 million recorded in Q2 2010.
  • Alnylam Pharmaceuticals' Current Deferred Tax Assets' 5-year high stood at $1.9 million during Q3 2010, with a 5-year trough of $1.9 million in Q4 2009.
  • Over the past 2 years, Alnylam Pharmaceuticals' median Current Deferred Tax Assets value was $1.9 million (recorded in 2010), while the average stood at $1.9 million.